Biohit GastroPanel enters into global market by co-operation with Randox
GastroPanel- availability expands substantially when Randox started the global sales of its CE-labelled MULTIPLEX GASROINTESTINAL PANEL-test based on the Biohit license (1). Randox is a British health technology enterprise operating on global market, with the annual turnover of around 730 million euro in 2021. GastroPanel is a diagnostic blood test developed by Biohit Oyj, detecting Helicobacter infection in the stomach, atrophic gastritis (stomach mucosal a trophy) as well as the level of gastric acid output, thus disclosing the potential risks associated with these conditions, e.g.